Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer

Bibliography

• SEER Stat Fact Sheets: thyroid. National Cancer Institute; Bethesda, MD. 2011. Available from: http://seer.Cancer.gov/statfacts/html/thyro.html#incidence-mortality [Last accessed 10 December 2012]
   Google Scholar
• DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon; 2004
   Google Scholar
• Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab 1959;19:152-61
   PubMed Web of Science ®Google Scholar
• Li N, Du X, Reitzel L, Impact of enhanced detection on the increase in thyroid cancer incidence in the US: review of incidence trends by socioeconomic status within the Surveillance, Epidemiology, and End Results registry, 1980-2008. Thyroid 2013;23(1):103-10
   PubMed Web of Science ®Google Scholar
• Kent WD, Hall SF, Isotalo PA, Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 2007;177:1357-61
   PubMed Web of Science ®Google Scholar
• American Thyroid Association (ATA) guidelines taskforce on thyroid Nodules and differentiated thyroid cancer. Cooper DS, Doherty GM, Haugen BR, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214
   PubMed Web of Science ®Google Scholar
• Pacini F, Castagna MG, Brilli L, Pentheroudakis G; ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii110-19
   PubMed Web of Science ®Google Scholar
• Kloos RT, Eng C, Evans DB, American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612
   PubMed Web of Science ®Google Scholar
• Panigrahi B, Roman SA, Sosa JA. Medullary thyroid cancer: are practice patterns in the United States discordant from American Thyroid Association guidelines? Ann Surg Oncol 2010;17:1490-8
   PubMed Web of Science ®Google Scholar
• Maruyama R, Suzuki H, Yamamoto E, Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer. Tumour Biol 2012;33:277-85
   PubMed Web of Science ®Google Scholar
• Trosko JE, Chang CC, Upham BL, Tai MH. Ignored hallmarks of carcinogenesis: stem cells and cell-cell communication. Ann N Y Acad Sci 2004;1028:192-201
   PubMed Web of Science ®Google Scholar
• Romitti M, Ceolin L, Siqueira DR, Signaling pathways in follicular cell-derived thyroid carcinomas. Int J Oncol 2013;42:19-28
   PubMed Web of Science ®Google Scholar
• Cerrato A, De Falco V, Santoro M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol 2009;43:143-55
   PubMed Web of Science ®Google Scholar
• Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313
   PubMed Web of Science ®Google Scholar
• Perez CA, Santos ES, Arango BA, Novel molecular targeted therapies for refractory thyroid cancer. Head Neck 2012;34:736-45
   PubMed Web of Science ®Google Scholar
• Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med 2012;2:a006502
   PubMed Web of Science ®Google Scholar
• Capp C, Wajner SM, Siqueira DR, Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 2010;20:863-71
   PubMed Web of Science ®Google Scholar
• Ramirez R, Hsu D, Patel A, Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2000;53:635-44
   PubMed Web of Science ®Google Scholar
• Donis-Keller H, Dou S, Chi D, Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6
   PubMed Web of Science ®Google Scholar
• Mulligan LM, Kwok JB, Healey CS, Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60
   PubMed Web of Science ®Google Scholar
• Elisei R, Cosci B, Romei C, Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008;93:682-7
   PubMed Web of Science ®Google Scholar
• Wells SA Jr, Gosnell JE, Gagel RF, Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72
   PubMed Web of Science ®Google Scholar
• Robinson BG, Paz-Ares L, Krebs A, Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664-71
   PubMed Web of Science ®Google Scholar
• Wells SA Jr, Robinson BG, Gagel RF, Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA) 2010 ASCO Annual Meeting Proceedings. J Clin Oncol 2010;28(15 Suppl):5503
   Google Scholar
• Thornton K, Kim G, Maher VE, Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2012;18:3722-30
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Bastholt L, Krause T, Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13:897-905
   PubMed Web of Science ®Google Scholar
• Schlumberger MJ, Elisei R, Bastholt L, Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz JP, Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen LS, Vokes EE, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13
   PubMed Web of Science ®Google Scholar
• Lam ET, Ringel MD, Kloos RT, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, Knopp MV, Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19
   PubMed Web of Science ®Google Scholar
• Ahmed M, Barbachano Y, Riddell A, Analysis of the efficacy and toxicity of sorafenib in thyroid cancer – a phase II study in a UK based population. Eur J Endocrinol 2011;165:315-22
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Sherman SI, Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349
   PubMed Web of Science ®Google Scholar
• Capdevila J, Iglesias L, Halperin I, Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012;19:209-16
   PubMed Web of Science ®Google Scholar
• Carr LL, Mankoff DA, Goulart BH, Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260-8
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11:962-72
   PubMed Web of Science ®Google Scholar
• Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011;7:617-24
   PubMed Web of Science ®Google Scholar
• Shapiro GI, McCallum S, Adams LM, A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs 2012;
   Web of Science ®Google Scholar
• Tibes R, Fine G, Choy G, A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;
   PubMed Web of Science ®Google Scholar
• Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc) 2011;47:857-68
   PubMed Web of Science ®Google Scholar
• Exelixis XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib. Exelixis, Inc.; San Francisco, CA. 2012. Available from: http://www.exelixis.com/investors-media/press-releases [Last accessed 10 December 2012]
   Google Scholar
• ClinicalTrials.gov, A service of the U.S. National Institutes of Health, Bethesda, MD. 2012. Available from: http://www.clinicaltrials.gov/ct2/results?term=cabozantinib&Search=Search [Last accessed 10 December 2012]
   Google Scholar
• Kurzrock R, Sherman SI, Ball DW, Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-6
   PubMed Web of Science ®Google Scholar
• Full prescribing information. Cometriq, Exelixis, Inc., San Francisco, CA. Available from: http:/www.cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf [Last accessed 10 December 2012]
   Google Scholar
• Choueiri TK, Pal SK, Cabanillas ME, Antitumor activity observed in a phase I drug–drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC) 2011 ASCO Annual Meeting Proceedings. J Clin Oncol 2011;29(Suppl 15):e13042
   Google Scholar
• Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects. ClinicalTrials.gov, a service of the U.S. National Institutes of Health, Bethesda, MD. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01493869?term=NCT01493869&rank=1 [Last accessed 10 December 2012]
   Google Scholar
• Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies. ClinicalTrials.gov, a service of the U.S. National Institutes of Health, Bethesda, MD. 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT00215605?term=renal+elimination+AND+cabozantinib&rank=1 [Last accessed 10 December 2012]
   Google Scholar
• Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan. ClinicalTrials.gov, a service of the U.S. National Institutes of Health, Bethesda, MD. 2012; Available from: http://www.clinicaltrials.gov/ct2/results?term=cabozantinib&Search=Search [Last accessed 10 December 2012]
   Google Scholar
• Torres KE, Zhu QS, Bill K, Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 2011;17:3943-55
   PubMed Web of Science ®Google Scholar
• You WK, Sennino B, Williamson CW, VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011;71:4758-68
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308
   PubMed Web of Science ®Google Scholar
• Verbeek HH, Alves MM, de Groot JW, The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 2011;96:E991-5
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Brose MS, Ramies DA, Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC) 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;30(Suppl 15):5547
   Google Scholar
• Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM). ClinicalTrials.gov, a service of the U.S. National Institutes of Health, Bethesda, MD. 2012. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00704730?term=NCT00704730&rank=1 [Last accessed 10 December 2012]
   Google Scholar
• Schoffski P, Elisei R, Müller S, EXAM Study Group. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;30(Suppl 15):5508
   Google Scholar